- Home
- HCP vs VKTX Comparison
HCP vs VKTX Comparison
Compare HCP & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCP
- VKTX
- Stock Information
- Founded
- HCP 2012
- VKTX 2012
- Country
- HCP United States
- VKTX United States
- Employees
- HCP N/A
- VKTX N/A
- Industry
- HCP EDP Services
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- HCP Technology
- VKTX Health Care
- Exchange
- HCP Nasdaq
- VKTX Nasdaq
- Market Cap
- HCP 6.9B
- VKTX 7.2B
- IPO Year
- HCP 2021
- VKTX 2015
- Fundamental
- Price
- HCP $33.74
- VKTX $49.58
- Analyst Decision
- HCP Hold
- VKTX Strong Buy
- Analyst Count
- HCP 14
- VKTX 10
- Target Price
- HCP $32.80
- VKTX $109.80
- AVG Volume (30 Days)
- HCP 1.5M
- VKTX 6.8M
- Earning Date
- HCP 12-05-2024
- VKTX 10-23-2024
- Dividend Yield
- HCP N/A
- VKTX N/A
- EPS Growth
- HCP N/A
- VKTX N/A
- EPS
- HCP N/A
- VKTX N/A
- Revenue
- HCP $627,625,000.00
- VKTX N/A
- Revenue This Year
- HCP $15.03
- VKTX N/A
- Revenue Next Year
- HCP $14.88
- VKTX N/A
- P/E Ratio
- HCP N/A
- VKTX N/A
- Revenue Growth
- HCP 15.72
- VKTX N/A
- 52 Week Low
- HCP $19.27
- VKTX $10.51
- 52 Week High
- HCP $34.21
- VKTX $99.41
- Technical
- Relative Strength Index (RSI)
- HCP 40.72
- VKTX 31.07
- Support Level
- HCP $34.00
- VKTX $62.50
- Resistance Level
- HCP $34.21
- VKTX $70.41
- Average True Range (ATR)
- HCP 0.14
- VKTX 5.16
- MACD
- HCP -0.01
- VKTX -2.29
- Stochastic Oscillator
- HCP 25.40
- VKTX 1.99
About HCP HashiCorp Inc.
HashiCorp Inc is engaged in solving the infrastructure challenges of cloud adoption by enabling an operating model that unlocks the full potential of modern public and private clouds. Its cloud operating model provides consistent workflows and a standardized approach to automate the processes involved in delivering applications in the cloud: infrastructure provisioning, security, networking, and application deployment. Its main commercial products are Terraform, Vault, Consul, and Nomad.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.